| Characteristic |
Value |
| Age |
51 - 85 (median, 63) |
| Gender |
M 63, F 4 |
| Stage |
Ι4, Ⅱ11, Ⅲ17, ⅣA 25, ⅣB 8, ⅣC 2 |
| T stage |
T1 9, T2 33, T3 16, T4a 8, T4b 1 |
| N stage |
N0 21, N1 11, N2a 2, N2b 17, N2c 6, N3 10 |
| Concurrent chemotherapy |
total, 61 patients |
| TPF regimen |
27 |
| CDDP-based regimen |
41 |
| DOC-based regimen |
46 |
| S-1 |
1 |
| None |
6 |
| Simultaneous thoracic EBRT for concurrent ESCC |
Yes 14, No 53 |
| CBVRR (%) |
1.2 - 23.7 (median, 6.5) |
| GTVRR (%) |
-23.6 to 88.1 (median, 55.3) |
| BWLR (%) |
-4.9 to 15.2 (median, 4.2) |
|
